Aquestive Therapeutics/$AQST
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aquestive Therapeutics
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Ticker
$AQST
Sector
Primary listing
Employees
142
Headquarters
Website
AQST Metrics
BasicAdvanced
$847M
-
-$0.69
1.99
-
Price and volume
Market cap
$847M
Beta
1.99
52-week high
$7.55
52-week low
$2.12
Average daily volume
3.6M
Financial strength
Current ratio
3.529
Quick ratio
3.127
Long term debt to equity
-50.298
Total debt to equity
-55.459
Interest coverage (TTM)
-3.10%
Profitability
EBITDA (TTM)
-51.994
Gross margin (TTM)
61.09%
Net profit margin (TTM)
-147.38%
Operating margin (TTM)
-119.19%
Effective tax rate (TTM)
0.02%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-31.12%
Return on equity (TTM)
120.37%
Valuation
Price to revenue (TTM)
14.958
Price to book
-9.58
Price to tangible book (TTM)
-9.58
Price to free cash flow (TTM)
-13.198
Free cash flow yield (TTM)
-7.58%
Free cash flow per share (TTM)
-0.53
Growth
Revenue change (TTM)
-24.38%
Earnings per share change (TTM)
98.19%
3-year revenue growth (CAGR)
-4.01%
3-year earnings per share growth (CAGR)
-26.76%
What the Analysts think about AQST
Analyst ratings (Buy, Hold, Sell) for Aquestive Therapeutics stock.
Bulls say / Bears say
The FDA accepted the New Drug Application for Anaphylm™ with a PDUFA date of January 31, 2026, positioning Aquestive to launch the first oral epinephrine film for anaphylaxis if approved.
Aquestive had a pro forma cash position of about $93.0 million as of December 31, 2024, including $21.4 million raised through its ATM facility, giving the company enough runway for near-term clinical and commercial milestones.
The AQST-108 epinephrine topical gel Phase 2a clinical trial is on track to begin in Q2 2025, expanding the company's proprietary pipeline beyond CNS and strengthening its differentiated drug delivery platform.
Aquestive reduced its full-year 2025 revenue guidance to $44–$50 million after Libervant shifted from full approval to tentative approval, highlighting execution and regulatory risks in the CNS pipeline.
First-quarter 2025 revenue dropped 28 percent year-over-year to $8.7 million, due to declines in Suboxone and royalty income, showing the company’s dependence on legacy licensed products amid pipeline delays.
Net loss widened to $22.9 million in Q1 2025 from $12.8 million a year earlier, and SG&A expenses rose to $19.1 million, raising concerns about cash burn ahead of potential Anaphylm approval.
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
AQST Financial Performance
Revenues and expenses
AQST Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aquestive Therapeutics stock?
Aquestive Therapeutics (AQST) has a market cap of $847M as of October 28, 2025.
What is the P/E ratio for Aquestive Therapeutics stock?
The price to earnings (P/E) ratio for Aquestive Therapeutics (AQST) stock is 0 as of October 28, 2025.
Does Aquestive Therapeutics stock pay dividends?
No, Aquestive Therapeutics (AQST) stock does not pay dividends to its shareholders as of October 28, 2025.
When is the next Aquestive Therapeutics dividend payment date?
Aquestive Therapeutics (AQST) stock does not pay dividends to its shareholders.
What is the beta indicator for Aquestive Therapeutics?
Aquestive Therapeutics (AQST) has a beta rating of 1.99. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.